Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 39 of 228 for:    EDN1

Proadrenomedullin and Microcirculation in Monitoring Organ Dysfunction in Patient With Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03931967
Recruitment Status : Completed
First Posted : April 30, 2019
Last Update Posted : July 18, 2019
Sponsor:
Information provided by (Responsible Party):
Abele Donati, MD, Università Politecnica delle Marche

Brief Summary:
This study evaluates the association between plasmatic levels of Mid Regional Proadrenomedullin (MR-proADM) and the sublingual microcirculation in critical care patients admitted with infection, sepsis or septic shock.

Condition or disease Intervention/treatment
Infection Sepsis Septic Shock Diagnostic Test: MR-proADM

Detailed Description:

MR-proADM (Mid Region proAdrenomedullin) is a fragment of 48 amino-acids of ADM (Adrenomedullin), a protein belonging to the super-family of calcitonin-related peptides. MR-proADM is released in a 1:1 ratio with its native protein ADM. Blood levels of ADM are high in several conditions including infection, sepsis of septic shock. MR-proADM seems to be a promising marker for early diagnosis, prognosis and mortality in sepsis and it is also related to sepsis-induced organ failure.

The microcirculatory and endothelial damages represent two corner stones of the sepsis pathophysiology. They involved the loss of functional capillaries density and the loss of red blood cells deformability, the endothelial cell disfunction induced by sepsis, the induction of the apoptosis and necrosis, the alteration in the capillary permeability due to the loss of vasomotor tone and control. Moreover sepsis is characterised by the increased levels of adhesion molecules and the consequent interaction between neutrophils and endothelium, the fibrin deposition and the activation of the coagulation.

The aim of the study is to evaluate the correlation between the alteration in microcirculation and the levels of MR-proADM.

MFI (Microvascular Flow Index) is a qualitative measurement of microcirculation and the microcirculatory alterations during sepsis are crucial in the pathophysiology of this syndrome. It is related to prognosis and mortality in patient with sepsis in ICU (Intensive Care Unit)

Studying the relations between MFI and MR-proADM in the first five days of ICU stay could represent a good way to connect the pathophysiological background to a laboratory marker for an early diagnosis and for a measure of prognosis in patient with infections.

It is also important to compare the levels of MR-proADM with the other microcirculatory parameters (Total Vessel Density, Perfused Vessels Density, Percentage of Perfused Vessels, DeBacker score, Flow Heterogeneity index) and with the parameters of glycocalix and endothelial disfunction (Perfused Boundary Region and Endothelin-1)

When inclusion criteria are present and there are no exclusion criteria, patients will be enrolled for this five-days long study. Informed consent will be taken from the patient before enrollment or from the legal representative but when the neurological conditions do not allow

At the beginning of the study anthropometric data will be collected together with the main clinical and laboratory parameters (systolic, diastolic and mean arterial pressure, heart rate, mechanical ventilation parameters, blood gas parameters, vasoactive therapy, main parameters for renal, hepatic and haematological function, infectious condition and cultures).

Arterial blood samples will be collected and blood will be immediately centrifuged and plasma and serum samples will be stored at -80°C for the measurement of MR-proADM and Endothelin-1.

Moreover at the beginning of the study, the day after and the fifth days from the enrolment, the main microcirculatory parameters will be taken through Incident Dark Field Technology. Glycocheck Technology will be used to collect glycocalix conditions.


Layout table for study information
Study Type : Observational
Actual Enrollment : 21 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Proadrenomedullin and Microcirculation in Monitoring Organ Dysfunction in Patient With Infection: Prospective Observational Study
Actual Study Start Date : November 8, 2018
Actual Primary Completion Date : June 4, 2019
Actual Study Completion Date : June 4, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis Shock

Group/Cohort Intervention/treatment
MR-proADM Diagnostic Test: MR-proADM
to evaluate the plasmatic level of MR-proADM and endothelin-1 in the first five days of ICU stay.




Primary Outcome Measures :
  1. Assessment of Microvascular Flow Index (MFI) [ Time Frame: Five days ]
    Correlation between plasmatic value of MR-proADM and variation in Microvascular Flow Index (MFI) in patients admitted in ICU with suspected infection. MFI is detected in vivo by Incident Dark Field (IDF) Imaging at sublingual microcirculation. It represents the quality of blood flow at microcirculatory level.

  2. Assessment of the concentration of Mid Regional Proadrenomedullin (MR-proADM) [ Time Frame: Five days ]
    Correlation between plasmatic value of MR-proADM and variation in Microvascular Flow Index (MFI) in patients admitted in ICU with suspected infection. Mid Regional Proadrenomedullin (MR-proADM, unity of measurement nmol/L) is measured through a specify immunoenzymatic assay. MR-proADM is a diagnostic and prognostic marker of infection and sepsis.


Secondary Outcome Measures :
  1. Cut-off for Microvascular Flow Index (MFI) based on Mid Regional Proadrenomedullin (MR-proADM) levels [ Time Frame: Five days ]
    Founding a MR-proADM cut-off which would be able to predict a variation in MFI in patients admitted in ICU with suspected infection.

  2. Assessment of patient's mortality [ Time Frame: Five days ]
    Correlation between mortality (in percentage) and plasmatic levels of MR-proADM, based on MR-proADM clearance.

  3. Assessment of new organ failure [ Time Frame: Five days ]
    Correlation between organ failures and MRproADM, based on daily calculation of Sequential Organ Failure Assessment Score(SOFA score, 0 best value up to 24 worst value).Score subscales:Respiratory(PaO2/FiO2 (mmHg)≥ 400,score 0,< 400,+1,< 300, +2,< 200 and mechanically ventilated,+3,< 100 and mechanically ventilated,+4);Nervous(Glasgow coma scale 15,score 0,13-14,+1,10-12 +2,6-9 and mechanically ventilated,score +3,<6,+4);Cardiovascular(Mean arterial pressure/vasopressors:MAP≥70 mmHg,score 0,MAP<70 mmHg,+1,dopamine≤5 µg/kg/min or dobutamine (any dose),+2,dopamine>5 µg/kg/min OR epinephrine≤0.1 µg/kg/min OR norepinephrine≤ 0.1µg/kg/min,+3,dopamine>15 µg/kg/min OR epinephrine>0.1µg/kg/min OR norepinephrine>0.1µg/kg,+4);Liver(Bilirubin(mg/dl)[μmol/L],< 1.2[< 20],score 0,1.2-1.9[20-32],+1,2.0-5.9[33-101], +2,6.0-11.9[102-204],+3,> 12.0[> 204],+4);Kidney(Creatinine (mg/dl)[μmol/L] < 1.2[< 110],score 0,1.2-1.9[110-170],+1,2.0-3.4[171-299],+2,3.5-4.9[300-440],+3,> 5.0[> 440], +4),Coagulation

  4. Assessment of Procalcitonine (PCT) [ Time Frame: Five days ]
    Correlation between PCT (Unity of measurement, ng/ml) and MR-proADM as combined score for outcome measurement in term of mortality.

  5. Assessment of other microcirculatory parameters in patient with sepsis or septic shock. [ Time Frame: Five days ]
    Correlation between plasmatic value of MR-proADM and variation in Perfused Vessels Density (PVD, unity of measure 1/mm), Percentage of Perfused Vessels (PPV, unity of measure %), Total Vessels Density (TVD, unity of measure mm/mm2), Flow Heterogeneity Index (FHI), DeBacker Score (unit of measure, 1/mm). The parameters are detected in vivo by Incident Dark Field (IDF) Imaging at sublingual microcirculation. MR-proADM is a diagnostic and prognostic marker of infection and sepsis.

  6. Mid Regional Proadrenomedullin (MR-proADM) in patient with difference infectious condition. [ Time Frame: Five days ]
    Comparison of the MR-proADM blood concentration (nmol/L) in patient with suspected infection, infection, sepsis and septic shock.

  7. Correlation between Mid Regional Proadrenomedullin (MR-proADM) and glycocalix and endothelial damage. [ Time Frame: Five days ]
    Association between plasmatic value of MR-proADM and variation in Perfused Boundary Region (PBR, the parameters is detected in vivo by Sidestream Dark Field (SDF) Imaging at sublingual microcirculation) and Endothelin-1. MR-proADM is a diagnostic and prognostic marker of infection and sepsis.


Biospecimen Retention:   Samples Without DNA
Dosage of MicroMRproADM, endothelin-1


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
20 patients with suspected infection, infection, sepsis or septic shock admitted to ICU
Criteria

Inclusion Criteria:

  • Suspected Infection, Infection, Sepsis or Septic Shock in patient admitted in ICU from no more than 24 hours and which have previously monitored blood pressure and have a central venous catheter in place.

Exclusion Criteria:

  • Age < 18 yo
  • Length of stay in ICU > 24 hours;
  • Length of stay in other hospital unit, ward or surgery > 48 hours;
  • Refusal of informed consent;
  • Conditions that do not allow the possibility of getting a monitoring of sublingual microcirculation (maxillofacial trauma, serious inability to jaw, copious blood loss or secretions from the mouth)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03931967


Locations
Layout table for location information
Italy
AOU Ospedali Riuniti Ancona - Università Politecnica delle Marche
Ancona, Italy, 60126
Sponsors and Collaborators
Università Politecnica delle Marche
Investigators
Layout table for investigator information
Principal Investigator: Abele Donati, MD, PhD UNIVERSITA' POLITECNICA DELLE MARCHE

Layout table for additonal information
Responsible Party: Abele Donati, MD, Clinical Professor, Università Politecnica delle Marche
ClinicalTrials.gov Identifier: NCT03931967     History of Changes
Other Study ID Numbers: MicroMRproADM
First Posted: April 30, 2019    Key Record Dates
Last Update Posted: July 18, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Abele Donati, MD, Università Politecnica delle Marche:
Sepsis
Septic shock
Microcirculation
Glycocalix
Proadrenomedullin
Organ dysfunction
Critical Care
Intensive Care
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Shock, Septic
Sepsis
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Shock
Adrenomedullin
Antihypertensive Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Cardiotonic Agents
Vasodilator Agents
Protective Agents